PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Methadone and Buprenorphine/Naloxone Perform Comparably in Rural Programs

methadonebuprenorphine/naloxoneopioid use disorderMOUDopioid agonist treatmentrural healthretrospective cohorttreatment retentionurine toxicology Behavioral Health / Addiction Medicine

Background Information

Methadone and buprenorphine/naloxone show similar efficacy in rural OUD treatment.

Understanding the effectiveness of methadone versus buprenorphine/naloxone in rural settings aids in improving treatment strategies for opioid use disorder. Both medications showed similar effectiveness in reducing opioid use and retaining patients over a year, with clinic site impacting outcomes. This study supports using both methadone and buprenorphine/naloxone in rural areas, highlighting site-specific factors over medication type. Methadone and buprenorphine/naloxone are equally effective in rural OUD treatment programs.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: MacCamy A, Khairy L, Wasser T, Gill G, Kenefick L, Schmidt A, Akana N, Hall L, Kwon K, Limberg N, Kirk-Lewis K, Lewis M, Owen M, McPherson SM, Miguel AQ

Citation: MacCamy A, Khairy L, Wasser T, et al. Methadone Versus Buprenorphine/Naloxone: Treatment Outcome Differences Among Individuals Receiving Medications for Opioid Use Disorders in Rural Treatment Settings-A 1-Year Retrospective Cohort Study. The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association. 2026;42(4):e70219. doi:10.1111/jrh.70219

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.